Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Will Ver­tex’s “pipeline-in-a-prod­uct” pay off?

That’s the bet be­hind the com­pa­ny’s $4.9 bil­lion ac­qui­si­tion of Alpine Im­mune Sci­ences and its mid-stage IgA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.